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IMS HEALTH, INC. V. A YOTTE: SMALL STEP FOR PRIVACY,
GIANT LEAP STILL NEEDED FOR PRESCRIPTION DATA PRIVACY
Kathryn M. Marchesini'
Electronic data use in United States industries provides a
means by which businesses aggregate, track, and manage
consumer information. In the health care industry, data mining
companies, pharmacies, and pharmaceutical manufacturers have
adopted electronic data use with prescription information. The use
of electronic prescription data as a commodity raises privacy
concerns which have prompted the formation of state laws
restricting its use. Data mining companies recently challenged a
New Hampshire law restricting the commercial use of prescription
data. In IMS Health, Inc. and Verispan, L.L.C. v. Kelly A. Ayotte
the First Circuit held that a state has the right to prohibit the
transfer, sale, and use of patient and prescriber-identifiable drug
data for commercial purposes. This Recent Development examines
the authority of and need for Congress to enact federal legislation
to achieve effective prescription data privacy, augmenting New
Hampshire's law and ensuring privacy throughout the country.
This analysis considers the effects of the court's narrow statutory
interpretation and extent to which states can curtail the
commercial use of prescription data. Moreover, existing federal
health information privacy protections do not go far enough to
protect prescriber-identifiable data, and federal law should
address the gap, especially as the health care industry transforms
and data management becomes borderless.
I. INTRODUCTION
Many United States industries, including health care, use
electronic personal data to provide business intelligence. 2 Using
1 J.D. Candidate, University of North Carolina School of Law, 2010.
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technology, companies gather, store, and analyze data to assist
business operations. For example, regardless of how retail
pharmacies4  obtain information to fill prescriptions,5  most
pharmacies electronically store prescription data in databases.6
Not only does this stored data contain the type and brand of drug,
dosage, and quantity dispensed, it includes the patient's name and
the prescriber's identity.7  Data mining companies purchase
electronically stored prescription data from pharmacies and
aggregate, manipulate, and sell the modified prescription data to
pharmaceutical manufacturers. 9  Through a business practice
2 See, e.g., WEBSTER'S NEW MILLENNIUM DICTIONARY OF ENGLISH, (Preview
ed. (v. 0.9.7) 2009), http://dictionary.reference.com/browse/business (defining
business intelligence as "the process of gathering information about a business
or industry matter; a broad range of applications and technologies for gathering,
storing, analyzing, and providing access to data to help make business
decisions") (last visited Apr. 1, 2009) (on file with the North Carolina Journal of
Law & Technology).
Id.
4 Pharmacies, insurance companies, and electronic transmission intermediaries
acquire and store data as part of the business they conduct. See IMS Health, Inc.
v. Ayotte, 550 F.3d 42, 73-74 (1st Cir. 2008), petition for cert. filed, 2009 WL
797587 (U.S. Mar. 27, 2009) (No. 08-1202).
Patients and doctors can submit information by paper, phone calls, or e-
prescribing. See generally Department of Health and Human Services, Overview
E-prescribing, http://www.cms.hhs.gov/eprescribing/ (last visited Apr. 1, 2009)
(on file with the North Carolina Journal of Law & Technology) (defining e-
prescribing as "a prescriber's ability to electronically send an accurate, error-
free, and understandable prescription directly to a pharmacy from the point-of-
care").
6 See generally ROBERT P. NAVARRO, ESSENTIALS OF MANAGED HEALTH
CARE, 299-303 (Peter R. Kongstvedt ed., Jones and Bartlett Publishers 2003)
(discussing pharmacy information systems and health informatics).
7 IMS Health, 550 F.3d at 45.
8 These companies purchase and compile prescription data in order to sell the
data to research and academic institutions, law enforcement agencies, and
private organizations. See Electronic Privacy Information Center (EPIC) - IMS
Health v. Ayotte, http://epic.org/privacy/imshealth/ (last visited Apr. 1, 2009)
(on file with the North Carolina Journal of Law & Technology).
9 IMS Health, 550 F.3d at 45 ("[T]hey purchase data ... aggregate the entries,
group them by prescriber, and cross-reference each physician's prescribing
history with physician-specific information available through the American
10 N.C. J.L.& TECH. ON. 96,98
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known as "detailing,"10 pharmaceutical sales representatives use
prescription data to conduct target marketing toward specific
doctors.11
Federal privacy protections provided by the Privacy Rule, 12
promulgated under the Health Insurance Portability and
Accountability Act (HIPAA),1 3 govern patients' protected health
information ("PHI").14 Pharmacies are not allowed to disclose PHI
Medical Association. The final product enumerates the prescriber's identity and
specialty, the drug prescribed, and kindred information.").
10 Detailing occurs when a pharmaceutical representative communicates with
a health care professional to provide pharmaceutical information and promote a
pharmaceutical product. Traditionally, pharmaceutical detailing involves face-
to-face communication; however, there has been increased use of information
technology through e-detailing. See generally Press Release, Manhattan
Research, L.L.C., Big Changes Ahead for Technology-Based Pharmaceutical
Detailing, Nov. 10, 2004, http://www.manhattanresearch.com/newsroom/
PressRelease/eDetailing_11 102004.aspx (last visited Mar. 9, 2009) (describing
technology-supported detailing) (on file with the North Carolina Journal of Law
& Technology). See also IMS Health, 550 F.3d at 44-45.
1 See IMS Health, 550 F.3d at 45.
12 See 45 C.F.R. §§ 164.514 (2008) (establishing regulations for the use and
disclosure of PHI). There is no mention of prescriber-identifiable prescription
data. See id.
13 The Health Insurance Portability and Accountability Act of 1996 (HIPAA),
Pub. L. No. 104-91, §§ 261-64 (1996) [hereinafter HIPAA]. The law's primary
purpose is to provide health insurance portability for individuals, with agency
rules focusing on the privacy of individuals' health information. See U.S.
Department of Health and Human Services-Office for Civil Rights (OCR),
Summary of the HIPAA Privacy Rule, (2003) [hereinafter Sunnary of the
HIPAA Privacy Rule], available at http://www.hhs.gov/ocr/privacy/hipaa/
understanding/summary/privacysummary.pdf ("The Standards for Privacy of
Individually Identifiable Health Information ('Privacy Rule') establishes . . . a
set of national standards for the protection of certain health information ....
The Privacy Rule standards address the use and disclosure of individuals' health
information-called 'protected health information' by organizations subject to
the Privacy Rule-called 'covered entities,' as well as standards for individuals'
privacy rights to understand and control how their health information is used.").
14 PHI includes any information about health status, provision of health care,
or payment for health care that can be linked to an individual. Eighteen
identifiers constitute PHI, including name, e-mail, and social security number.
Data is considered de-identified (and may be used) if all of these identifiers are
removed. See 45 C.F.R. § 164.514(b)(2) (2007).
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to a third party, except as expressly permitted by the Privacy
Rule. 16  The HIPAA Privacy Rule, however, does not prevent
pharmacies from disclosing prescriber-identifiable prescription
data. Therefore, data-miners can purchase and sell prescriber-
identifiable prescription data from pharmacies, allowing for
detailing to occur.
Although the sale of electronic prescription data is a lucrative
business and drug companies consider this data an invaluable
resource,19 the data's transfer and use have implications for a
prescriber's privacy. Prescribers have the right to be left alone. 20
" Pharmacies that transmit health care information are "covered entities"
within the meaning of the HIPAA Privacy Rule because they are "health care
providers" that transmit "health information" in electronic form in connections
with a "transaction" covered by HIPAA. See 45 C.F.R. § 160.103 (2008). They
provide a health service by filling prescriptions and then billing a consumer's
health insurance company for its portion of the prescription's cost. See §§ 45
C.F.R. 160.130, 164.502(c) (2007) (requiring covered entities utilizing PHI to
de-identify the information and comply with the disclosure provisions of the
Privacy Rule).
16 See 45 C.F.R. §§ 160.102, 164.502(c) (2007) (Pharmacies can disclose PHI
to data mining companies if they de-identify it in accordance with the de-
identification rules). See also American Recovery Reinvestment Act of 2009
(ARRA), Health Information Technology for Economic and Clinical Health Act
(HITECH Act), 111 Pub. L. No. 5, § 13405, 123 Stat. 115 (2009) (stating that a
covered entity or business associate cannot directly or indirectly receive
payment for any PHI unless it first obtains a valid authorization from the
individual whose PHI is to be disclosed).
17 PHI does not include prescriber-identifiable data. See HIPAA, supra note
13.
1 Stephanie Saul, Federal Court Upholds Drug Privacy Law, N.Y. TIMES,
Nov. 19, 2008, at 310, available at http://www.nytimes.com/2008/11/19/
business/i 9drug.html.
19 Associated Press, NH Prescription Privacy Law Upheld,
BUSINESSWEEK.COM, (Nov. 18, 2008) ("The data compiled by companies like
IMS and Verispan is considered invaluable by the tens of thousands of drug
company salespeople . . . who use it to identify doctors' drug preferences,
whether they favor brand-name medicines over generics, and whether they have
been willing to prescribe new drugs to the market.") (on file with the North
Carolina Journal of Law & Technology).
20 See Louis Brandeis & Samuel Warren, The Right to Privacy, 4 HARV. L.
REv. 193, 193 (1890).
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Privacy is an individual's ability to decide "when, how, and to
what extent information about [him or her] is communicated to
others."21 In essence, once a pharmacy fills a prescription,
prescriber privacy rights seem to disappear because pharmacies
essentially make this information "public" when they sell
prescription data.
Many groups have identified problems associated with health
data mining and have taken steps to minimize the commercial use
of prescription data.22 In 2006, New Hampshire enacted a
Prescription Information Law, specifically prohibiting certain in-
state licenses, sales, uses, or transfers of patient and prescriber-
identifiable prescription data for use in detailing.23 The law was
the first of its kind in the nation. The First Circuit's recent
21 DANIEL J. SOLOVE ET AL., INFORMATION PRIVACY LAW, 41 (Erwin
Chemerinsky et. al ed., Aspen Publishers 2006) (citing ALAN F. WESTIN,
PRIVACY AND FREEDOM (1967)). Many theorists view privacy as the control
over personal information. See, e.g., Randall P. Bezanson, The Right to Privacy
Revisited: Privacy, News, and Social Change, 80 CAL. L. REv. 1133, 1810-1990
(1992). But see Anita L. Allen, Privacy as Data Control: Conceptual,
Practical, and Moral Limits of the Paradigm, 32 CONN. L. REv. 861, 862 (2000)
(viewing the privacy-control paradigm as problematic because of limits on its
plausibility).
22 The Prescription Project, Prescription Data Mining Fact Sheet, 2, Nov. 19,
2008, available at http://www.prescriptionproject.org/tools/solutions-factsheets
/files/0004.pdf ("Physician organizations, patient advocacy groups, and
legislators have . . . taken steps . . . in the following states: New Hampshire...
Vermont,... Maine, ... Hawaii, Maryland, Massachusetts, Nevada, New York,
Washington, and the District of Columbia . . . . All existing or proposed
legislation restricts only the sale and use of patient or prescriber data specifically
for marketing or commercial purposes. They do not restrict [it] for other
purposes, including . . . insurance reimbursement, dispensing prescriptions,
utilization review, public health research, law enforcement purposes, controlled
substances monitoring, adverse effects reporting, or compliance with Medicaid
or private insurance formularies and rules.") (last visited Feb. 13, 2009) (on file
with the North Carolina Journal of Law & Technology).
23 See N.H. REV. STAT. ANN. § 318:47-f (2006) [hereinafter NH Prescription
Information Law]; Rick Valliere, First Circuit Upholds New Hampshire Law
Banning Sale of Doctor Prescription Data, PRIVACY L. WATCH, Nov. 19, 2008,
available at http://www.bna.com/products/ip/pwdm.htm (on file with the North
Carolina Journal of Law & Technology).
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decision in IMS Health, Inc. v. Ayotte24 upheld the controversial
Prescription Information Law when challenged by two data mining
companies on constitutional grounds. The court held that the law
did not violate the First Amendment25 because the law regulates
conduct26 and did not violate the Commerce Clause27 because it
affects only in-state transactions. 28
Even though the state law aims to restrict disclosure and use of
prescriber-identifiable prescription data, loopholes exist that allow
the occurrence of these state-prohibited commercial activities. 29In
turn, Congress should enact a federal law to achieve effective
prescription data privacy. Part II of this Recent Development
focuses on the New Hampshire Prescription Information Law at issue
in the IMS Health decision, discussing privacy concerns and the
court's overall decision regarding the law's constitutionality. Part III
argues that although the IMS Health decision constitutes precedent to
uphold state laws curbing commercial use of prescriber-identifiable
data, even in light of existing federal statutes and regulations
protecting health information, threats to privacy remain. Part IV
proposes that federal legislation should address this overarching
issue, as data mining and pharmaceutical companies are multi-state
enterprises by which electronic data exchanges often occur outside
the state's borders. Finally, with the increased use of health
information technology ("health IT") in the United States, Part V
highlights the general need for oversight of and safeguards for
prescriber-identifiable data protection.
24 IMS Health, Inc. v. Ayotte, 550 F.3d 42, 46 (1st Cir. 2008), petition for cert.
filed, 2009 WL 797587 (U.S. Mar. 27, 2009) (No. 08-1202) (upholding the
constitutionality of NH Prescription Infornation Law).
25 U.S. CONST. amend. I. This Recent Development will not explore the First
Amendment issues.
26 IMS Health, 550 F.3d at 50-53 (accepting the government's argument that
the law regulates conduct rather than commercial speech).
27 Id. at 64.
28 See id. at 62-64.
29 See id. at 103-04 (Lipez, J., dissenting).
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II. NEW HAMPSHIRE PRESCRIPTION INFORMATION LAW AND
THE IMS HEALTH DECISION
The New Hampshire Prescription Information Law states
"[Lr]ecords relative to prescription information containing patient-
identifiable and prescriber-identifiable data shall not be licensed,
transferred, used, or sold by any pharmacy benefits manager,
insurance company, electronic transmission intermediary, retail,
mail order, or Internet pharmacy or other similar entity, for any
commercial purpose,"30 except for certain limited purposes. The
state justifies the law by arguing that it has a substantial interest in
protecting the privacy interests of its constituents, safeguarding
patient health, and promoting containment of prescription drug
costs.32 The foremost concern of this Recent Development is
privacy interests.
A. Privacy Interests, Threats, and Harms
The aggregation, insecurity, and secondary use of prescription
data are forms of information processing that pose a risk to patients
and prescribers.33 While prescription data must be de-identified 34
30 N.H. REV. STAT. ANN. § 318:47-f (2006) ("Commercial purpose includes,
but is not limited to advertising, marketing, promotion, or any activity that could
be used to influence sales or market share of a pharmaceutical product, influence
or evaluate the prescribing behavior of an individual health care professional, or
evaluate the effectiveness of a professional pharmaceutical detailing sales
force.").
31 Id. (listing acceptable limited purposes as "pharmacy reimbursement;
formulary compliance; care management; utilization review by a health care
provider, the patient's insurance provider or the agent of either; health care
research; or as otherwise provided by law").
32 IMS Health, 550 F.3d at 47, 75.
3 See Daniel J. Solove, A Taxonomy of Privacy, 154 U. PA. L. REv. 477, 490
(2006).
34 See generally William Landi & R. Bharat Rao, Secure De-identification and
Re-identification, American Medical Informatics Association Annual
Symposium Proceedings 905 (2003) available at http://www.pubmedcentral
.nih.gov/articlerender.fcgi?artid=1479909 ("The term de-identified data refers to
patient data from which all information that could reasonably be used to identify
the patient has been removed (e.g., removing name, address, social security
10 N.C. J.L.& TECH. ON. 96, 103
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to protect patient privacy,35 the risk of re-identification remains. 36
For instance, the potential secondary use and sharing of
prescription data with a data-miner could cause harm to the dignity
of a patient or prescriber. This Recent Development focuses on
the privacy interests of prescribers. 39
In addition to the health care industry's cultural norms and the
sensitive nature of health information, prescribers have no desire
for data-miners and/or detailers to have access to their prescribing
behavior.40 Government officials, as third parties, do have access
number, etc. . .).") (on file with the North Carolina Journal of Law &
Technology).
3 The HIPAA Privacy Rule forbids pharmacies to disclose patient-identifiable
information to data mining companies without express patient authorization to
do so. See 45 C.F.R. § 164.508(a)(3) (2007).
36 See generally Supplemental Brief for the Electronic Privacy Information
Center et al. as Amici Curiae Supporting Defendant-Appellant at 6. IMS Health,
Inc. v. Ayotte, No. 07-1945 (1st Cir. Aug. 20, 2007) (arguing that de-identified
data can be easily re-identified by linking to public records, as one researcher
was able to identify eighty-seven percent of the United States population
through the use of birth, gender, and zip code information); Christine Porter, De-
Identified Data and Third Party Data Mining: The Risk of Re-Identication of
Personal Information, 5 SHIDLER J.L. CoM. & TECH. 3 (2008).
3 See Solove, supra note 33, at 521-22 ('"Secondary use' is the use of data
for purposes unrelated to the purposes for which the data was initially collected
without the data subject's consent . . . . The harm is a dignitary one, emerging
from denying people control over the future use of their data, which can be used
in ways that have significant effects on their lives.").
38 See Brandeis & Warren, supra note 20, at 197, 214.
39 To the extent the law prohibits pharmacies from selling or otherwise
disclosing patient-identifiable prescription data for commercial purposes,
HIPAA provides for the protection of patient health information. See HIPAA,
supra note 13. See also U.S. Dept. of Health and Human Services (HHS) Office
for Civil Rights (OCR), Health Information Privacy Resolution Agreement,
(Jan. 15, 2009) available at http://www.hhs.gov/ocr/privacy/hipaa/enforcement/
examples/cvsresagrcap.pdf. To settle potential violations of the HIPAA Privacy
Rule, CVS agreed to pay $2.25 million in a case regarding protected health
information. Id.
40 See generally Saul, supra note 18 ("Such legislation has been urged by
doctors who object to the disclosure of their prescribing patterns.").
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to prescriber-identifiable data for specific public health reasons.41
However, disclosing data to third-party data-miners for
commercial purposes invades a prescriber's privacy.42 The data
provides details about prescribers' prescription behavior, enabling
detailers "to zero in on physicians who regularly prescribe
competitors' drugs, . . . large quantities of drugs for particular
conditions, . . . and 'early adopters."'43 Moreover, under the
doctor-patient relationship,44 patients likely consider prescription
data as private.45 In turn, prescribers could suffer reputational
harm because patients may question whether a prescriber's overall
basis for prescribing a particular brand-name drug is a medical
reason, or a preference resulting from a personal solicitation. New
41 See, e.g., Comprehensive Drug Abuse Prevention and Control Act, 21
U.S.C. § 801 (2006); National All Schedules Prescription Electronic Reporting
Act (NASPER), Pub. L. No. 109-60, 119 Stat. 1979 (2005). Thirty-eight states
have enacted legislation for prescription drug monitoring programs (PDMPs) to
monitor the illegal use of prescriptions for narcotics and other controlled
substances. See generally U.S. Dept. of Justice, Drug Enforcement Agency,
Office of Diversion Control, State Prescription Drug Monitoring Programs,
Questions and Answers, http://www.deadiversion.usdoj.gov/faq /rx monitor.htm
#1 (last visited Mar. 10, 2008) (on file with the North Carolina Journal of Law
& Technology).
42 See Solove, supra note 21.
43 IMS Health, Inc. v. Ayotte, 550 F.3d 42, 47 (1st Cir. 2008), petition for cert.
filed, 2009 WL 797587 (U.S. Mar. 27, 2009) (No. 08-1202) (defining early
adopters as "physicians with a demonstrated openness to prescribing drugs that
have just come onto the market").
44 See, e.g., Vanessa Ho, Bill Would Make Prescription Data Private, (Jan. 23,
2009) Seattle Post-Intelligencer Blogs, http://blog.seattlepi.nwsource.com/
healthreport/archives/160219.asp ("The sharing of prescription information for
marketing purposes without consent seems to violate the spirit of privacy law,
and destroys the confidentiality of the doctor-patient relationship.") (last visited
Feb. 15, 2009) (on file with the North Carolina Journal of Law & Technology).
45 Patients have an expectation of privacy to the extent prescription
information is not needed to fill a prescription or process an insurance claim.
See, e.g., Donald Nelson, Why Does Medicine Need Standards?, (Aug. 1997),
Medical Computing Today, http://www.medicalcomputing.org/archives/Oastand
why.php ("Associating data with the wrong patient is potentially dangerous, and
disclosing data to inappropriate recipients violates the patient's expectation of
privacy and the professional's commitment to confidentiality.") (last visited May
27, 2009).
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Hampshire's concern is the exploitation of the mined data by
pharmaceutical detailers that utilize the massive collection of
prescription data in marketing brand-name drugs to prescribers.46
B. IMS Health Decision
IMS Health, Inc. and Verispan, L.L.C., companies in the health
data mining business, challenged the Prescription Information Law
on First Amendment and Commerce Clause grounds, claiming that
the law infringed on commercial free s eech 47 and regulated
activity wholly outside New Hampshire. As the Commerce
Clause prevents state governments from burdening the free flow of
goods from one state to another,49 a law that purports to regulate
conduct occurring wholly outside the enacting state "outstrips the
limits of the enacting state's constitutional authority and, therefore,
is per se invalid."50  Although the law does not provide explicit
geographic limitations, the court narrowly interpreted the law's
scope to be the regulation of in-state transactions. Since the
Prescription Information Law only regulates in-state commercial
46 IMS Health, 550 F.3d at 46.
47 Id. at 48. The First Circuit Court held that the statute provision principally
regulated conduct, not speech. Id. at 52. Additionally, the law is of no First
Amendment significance because the challenged provision only restricts the
data-miner's ability "to aggregate, compile, and transfer" information as a
commodity. See id. at 52-53 (deciding the First Amendment claim on an
alternative ground).
48 Id. at 62-63.
49 Id. at 62 (citing Alliance of Auto. Mfrs. v. Gwadosky, 430 F.3d 30, 35 (1st
Cir. 2005)).
'0 Id. at 62-63 (quoting Alliance, 430 F.3d at 35) ("The proper mode of
analysis under this so-called 'dormant Commerce Clause' depends upon the
scope of the challenged statute .... ).
" See IMS Health, Inc. v. Ayotte, 550 F.3d 42, 63 (1st Cir. 2008) (1st Cir.
2008), petition for cert. filed, 2009 WL 797587 (U.S. Mar. 27, 2009) (No. 08-
1202) (citing K-S Pharms., Inc. v. Am. Home Prods. Corp., 962 F.2d 728, 730
(7th Cir. 1992)) ("[S]tate statutes should be presumed to govern only conduct
within the borders of the enacting state. . . . [I]t would make no sense to read the
statute to regulate out-of-state transactions when the upshot of doing so would
be to annul the statute.").
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conduct, 52 the majority held that the law did not violate the
Commerce Clause.
On the contrary, in IMS Health, Judge Kermit Lipez dissented
from the majority's Commerce Clause holding, and noted that due
to the law's narrow construction, the law's impact in New
Hampshire appears "negligible."54 If the law does not apply
outside the state, the law "loses all of its force and effectiveness"
because a retail pharmacy in New Hampshire could transfer
prescriber-identifiable prescription data to its parent company in
another state." The parent company could transfer this data to
data-miners outside New Hampshire. 6 No barriers to the use of
this data exist for data-miners and detailers." Thus, Judge Lipez
would have remanded the issue for further fact-finding regarding
the flow of prescriber-identifiable data" to determine whether the
law violates the dormant Commerce Clause.59
52 Id. at 63-64 (citing Reply Brief of Appellant at 13, IMS Health, Inc. v.
Ayotte, 530 F.3d 42 (1st Cir., 2008)) ("[T]he New Hampshire Attorney
General-the state official charged with enforcing its laws-has exhorted us to
read the Prescription Information Law to relate only to activity that takes place
domestically."').
1 The Commerce Clause of the U.S. Constitution applies to commerce
"among the several States." See U.S. CONST. art. I, § 8, cl. 3.
54 IMS Health, 550 F.3d at 104 (Lipez, J., dissenting).
" Id. at 103.
56 Id.
57Id.
58 See id. at 106; see also id. at 102-03 ("There is a puzzling disconnect
between the Attorney General's contention that the Act governs only
transactions that take place within New Hampshire and the plaintiffs' contention
that all of the conduct that the Act purports to regulate occurs outside the
State.").
59 IMS Health, 550 F.3d at 105 (Lipez, J., dissenting) (citing Pharm. Care
Mgmt. Ass'n v. Rowe, 429 F.3d 294, 311 (1st Cir. 2005)) ("[T]he dormant
Commerce Clause . . . is not absolute and in the absence of conflicting
legislation by Congress, 'the States retain authority under their general police
powers to regulate matters of legitimate local concern, even though interstate
commerce may be affected."'). The dormant Commerce Clause focuses on the
extent to which the Commerce Clause constrains a state's interference with
interstate commerce, absent federal law. Since there is no federal statute on-
point regarding this issue, federal limits apply to state regulation of interstate
10 N.C. J.L.& TECH. ON. 96, 107
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III. STATE LAW ADDRESSES ONLY A SUBSET OF A NATIONWIDE
DATA PRIVACY ISSUE
A. Effect and Limited Scope of Prescription Information Law
As a result of the IMS Health decision to uphold the
Prescription Information Law, when consumers fill a prescription
at a local pharmacy, corresponding prescription data will not be
licensed, transferred, sold, or used for commercial purposes within
the state of New Hampshire.60 Nevertheless, the commercial use
of prescriber-identifiable prescription data purchased outside the
state or transferred for other purposes within the state still threatens
the privacy of New Hampshire patients.61 The IMS Health
decision undercuts the very privacy concern which the statute was
62intended to address. The court's narrow interpretation of the law
does not fully prevent third parties from accessing prescriber-
identifiable data for commercial purposes. 63  An out-of-state
commercial data transfer not specifically prohibited 64 would be
65
outside the law's scope. A detailer could buy and use New
commerce, prohibiting laws that discriminate against or improperly burden
interstate commerce. See, e.g., Gibbons v. Ogden, 22 U.S. 1 (1824).
60 Sheri Qualters, 1st Circuit Upholds Law Barring Marketers From Using
Data on Doctors' Prescriptions, NAT'L L. J., (Nov. 20, 2008), http://www.
law.com/jsp/article.jsp?id=1202426155608 (last visited Feb. 13, 2009) (on file
with the North Carolina Journal of Law and Technology).
See IMS Health, Inc.. (Lipez, J., dissenting) ("[T]he statute's impact in New
Hampshire appears negligible if it truly governs only transactions that occur
within the state.").
62 See id. at 47.
See Melissa Ngo, Federal Court Upholds New Hampshire Prescription
Privacy Law, Privacy Lives Blog (Nov. 20, 2008), http://www.
privacylives.com/federal-court-upholds-new-hampshire-prescription-privacy-
law/2008/11/20/ (last visited Feb. 13, 2009) (on file with the North Carolina
Journal of Law & Technology) ("The New Hampshire legislature also noted the
privacy interests that patients and physicians have in preventing third parties
from receiving in-depth data on every prescription written. . . . [T]here are
privacy problems that can arise from 'de-identified data."'); id. at 104 (Lipez, J.,
dissenting).
64 See § 318:47-f, supra note 30.
See IMS Health, 550 F.3d at 103-04 (Lipez, J., dissenting) ("It's undisputed
that the pharmacy, as a part of its routine practices ... transfers the information
10 N.C. J.L.& TECH. ON. 96, 108
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Hampshire prescriber-identifiable data66 outside the state for any
commercial purpose prohibited within the state,67  ultimately
circumventing the legislature's intent. Hence, a detailer's use of
prescriber-identifiable data within the state would not violate the
law, as long as the detailer acquires the data outside the state.68
The Prescription Information Law seems to be ineffective by
design. It restricts the in-state disclosure and use of prescribers'
prescribing behavior for target marketing purposeS69 but does not
explicitly prohibit detailing. 70  Additionally, the law does not
explicitly forbid "the collection, use, transfer, or sale of patient and
prescriber de-identified data by zip code, geographic region, or
medical specialty for commercial purposes."71 Consequently, data
privacy is still vulnerable to attacks because of sophisticated re-
72identification programs.
in the ordinary course of its business from a data center in the state to data
centers outside the state . . . . The explicit language of the Act does not appear
to impose such a restriction on the original transfers of data by New Hampshire
pharmacies to entities outside the state. Transactions involving those
commercial purposes occur farther downstream, and, so far as the record shows,
primarily outside the state.").
66 As an entity covered by the HIPAA regulations, a pharmacy that transmits
health care information must de-identify patient health information. See 45
C.F.R. § 160.103 (2007).
67 See IMS Health, 550 F.3d at 104 (1st Cir. 2008) (Lipez, J., dissenting),
petition for cert. filed, 2009 WL 797587 (U.S. Mar. 27, 2009) (No. 08-1202).
68 Cf id. at 64 (withholding judgment on "whether the purchasers could
subsequently make use of the aggregated data in New Hampshire").
69 Saul, supra note 18. See N.H. REv. STAT. ANN. § 318:47-f (2006).
70 See IMS Health, 550 F.3d at 103 (Lipez, J., dissenting) ("Because if Rite
Aid's pharmacy in New Hampshire can transfer to its parent in Pennsylvania and
its parent can transfer to IMS . . . in Pennsylvania, that's not prohibited. And
then they can transfer it to Pfizer, wherever Pfizer's headquarters are outside of
New Hampshire; and if Pfizer can then use it outside of New Hampshire for all
of these various purposes that are prohibited, then there's absolutely no force or
effect to this statute.").
71 See N.H. REV. STAT. ANN. § 318:47-f (2006).
72 Ngo, supra note 63 ("Individuals can be re-identified using information
such as zip code, date of birth, and gender and then comparing that data to
publicly available information. Such information is easily accessible via birth
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States regulate the practice of medicine and have jurisdiction
over health care licensing requirements. However, a state's
ability to regulate the commercial use of prescriber-identifiable
data presents a challenge because of the nature of the issue. Due to
the free flowing nature of electronic data, prescription data does
not adhere to the confines of state borders. In essence, data can be
considered borderless. Pharmacies may store prescription data
74
remotely to enable centralized access. The prescription data may
not physically reside where it is collected. Thus, an out-of-state
transfer of prescription data is often necessary to fill a
prescription.76 Although New Hampshire regulates a physician's
ability to write prescriptions, state regulation of unauthorized
and death records, incarceration reports, voter registration files, and driver's
licensing information.").
7 State Medical Boards license physicians to practice medicine within the
state and provide oversight and disciplinary actions of the overall profession.
See, e.g., New Hampshire Medical Practice Act, N.H. REv. STAT. ANN. § 329:1,
17 (2008).
74 Data management practices could be in the form of "Cloud Computing" in
which users do not necessarily have control over the technology infrastructure
"in the cloud" that support them. See, e.g., Cloud Computing: The Evolution of
Software-as-a-Service, Knowledge@W.P. Carey, Jun. 4, 2008, http://knowledge
.wpcarey.asu.edu/article.cfn?articleid=1614 (on file with the North Carolina
Journal of Law & Technology). See also Stephanie Condon, FTC Questions
Cloud-Computing Security, CNET.com, Mar. 17, 2009, http://news.
cnet.com/8301-13578 3-10198577-38.html. The Federal Trade Commission
(FTC) is examining the practice of cloud computing and its privacy and security
implications. Legislative Hearing on Data Accountability and Protection Act,
and H.R. 1319, the Informed P2P User Act Before the H. Comm. on Energy and
Commerce, Subcommittee on Commerce, Trade, and Consumer Protection,
111th Cong. 16 (2009) (statement of Eileen Harrington, Acting Director of the
Bureau of Consumer Protection at the FTC), available at
http://energycommerce.house.gov/Press 111/20090505/testimony harrington.
pdf (on file with the North Carolina Journal of Law & Technology).
7 See id.
76 See IMS Health, Inc. v. Ayotte, 550 F.3d 42, 102 (1st Cir. 2008), (Lipez, J.
dissenting) petition for cert. filed, 2009 WL 797587 (U.S. Mar. 27, 2009) (No.
08-1202) ("It is undisputed that none of the plaintiffs' transactions take place
within New Hampshire . . .. IMS and Verispan obtain all of their prescription
information, including information on prescriptions filled in New Hampshire,
from computers that are located outside of New Hampshire."').
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disclosure and use of prescriber-identifiable data does seem to be
effective because the data may not reside within the state's
borders. Therefore, federal legislation needs to address this issue.
B. Existing Information Privacy Case Law, Statutes, &
Regulations
While the Supreme Court has not fully resolved the issue
77
regarding the disclosure of consolidated private data, Whalen v.
Roe7 8 serves as the foundational case for recognizing informational
privacy.79 In Whalen the Supreme Court hinted that there may be
an individual right to nondisclosure of personal information in
certain settings. Although recognized, this informational privacy
right is not unlimited.80 The Supreme Court has yet to define the
scope of such privacy protection.
7 Whalen v. Roe, 429 U.S. 589, 605-06 (1977) ("We therefore need not, and
do not, decide any question which might be presented by the unwarranted
disclosure of accumulated private data-whether intentional or unintentional-
or by a system that did not contain comparable security provisions.").
78 Id. at 605 (There is a "threat to privacy implicit in the accumulation of vast
amounts of personal information in computerized data banks."); id. at 599
(noting that there was an "individual interest in avoiding disclosure of personal
matters").
79 Nicolas P. Terry & Leslie P. Francis, Ensuring the Privacy and
Confidentiality of Electronic Health Records, 2007 U. ILL. L. REv. 681, 710
(2007).
80 Several federal courts have held that this constitutionally protected privacy
right extends to medical and prescription records. See, e.g., Herring v. Keenan,
218 F.3d 1171, 1175 (10th Cir. 2000); F.E.R. v. Valdez, 58 F.3d 1530, 1535
(10th Cir. 1995) (holding that there was a compelling state interest to prevent
Medicaid fraud when psychiatric records were seized pursuant to a state search
warrant); Doe v. Southeastern Pennsylvania Transportation Authority, 72 F.3d
1133, 1138 (3rd Cir. 1995) (recognizing a constitutional right to privacy in a
patient's prescription records); Lankford v. City of Hobart, 27 F.3d 477, 479-
481 (10th Cir. 1994) (noting that police chief's seizure of police dispatcher's
medical records from a local hospital without her consent or warrant is an
invasion of privacy because it violates the Equal Protection Clause of the
Fourteenth Amendment); A.L.A. v. W. Valley City, 26 F.3d 989, 990 (10th Cir.
1994) (noting that an individual's confidential medical information is entitled to
constitutional privacy protection when a police officer discloses results of an
arrestee's HIV test because an individual has a reasonable expectation of
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Technology has played a significant role in the development of
information privacy law.82 To date, Congress has approached the
technological assault on privacy in specific industries such as
finance, entertainment, and health, by piecemealed consumer
privacy protection laws.83  Although these laws govern the
collection, disclosure, and use of certain types of personal data, no
federal privacy law84 comprehensively governs the commercial use
and disclosure of prescriber-identifiable prescription data.85 Even
with federal privacy protections provided by the HIPAA Privacy
privacy, or he suffered an "injury in fact" as a result of the unlawful disclosures,
regardless of the validity of the information). But see U.S. v. Sutherland, 143 F.
Supp. 2d 609, 613 (W.D. Va. 2001) (holding that individual prescription records
from a hospital could be subpoenaed because of the government's interest in
obtaining the information was compelling).
81 See Lisa L. Dahm, et al., Privacy, in E-HEALTH BUSINESS AND
TRANSACTIONAL LAw 47, 53 (Barbara Bennett ed., 2002).
82 See Brandeis & Warren, supra note 20, at 195 (citing the technology
invention of photography as a compelling reason to consider the right to
privacy).
83 See, e.g., Fair Credit Reporting Act, 15 U.S.C. § 1681 (2006); Gramm-
Leach-Bliley Financial Services Modernization Act, 15 U.S.C. § 6801 (2006);
The Video Privacy Protection Act, 18 U.S.C. § 2710 (2006); The Drivers
Privacy Protection Act (DPPA), 18 U.S.C. § 2721 (2006); Cable Television
Privacy Act, 47 U.S.C. § 551 (2006); Health Insurance Portability and
Accountability Act (HIPAA), Pub. L. 104-191, §§ 261-264, 110 Stat. 1936
(1996).
84 A federal landscape of health-related laws exists that addresses specific
issues. However, none of the existing federal laws address the commercial use
of prescriber-identifiable prescription data. See, e.g., 45 C.F.R. § 160.103
(2007) (noting that privacy regulations do address and govern the commercial
use of prescription data that contains patient-identifiable prescription data);
Consolidated Omnibus Budget Reconciliation Act (COBRA), 29 U.S.C. § 1132
(2006); Employee Retirement Income Security Act (ERISA), 29 U.S.C. § 1001
(2006).
85 See Dahm, supra note 81, at 54 ("The existing federal laws and regulations
that relate to privacy of health information are each limited in some way-either
they protect only a specific portion of health information (e.g., substance abuse
and treatment records), or they protect the health information of only a portion
of the population (e.g., children), or they address only information that is
handled electronically (e.g., electronic signatures), or they apply to only
particular segment of the health care industry (e.g., 'covered entities').").
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Rule,8 6 prescriber-identifiable data can be sold to and by data
miners.87  Similarly, no federal regulation de-identification
standards exist for prescriber-identifiable prescription data.88
Companies' health data mining practices have triggered state
legislative action 89 and associated litigation 90 across the United
States. 91 The American Medical Association (AMA) has tried to
mitigate the threat to privacy through its voluntary, opt-out
Physician Data Restriction Program.92 The program provides
physicians with a choice to restrict access to prescription data.
93
86 See Summary of the HIPAA Privacy Rule, supra note 13.
87 See 45 C.F.R. § 164.514(b)(2) (2007).
8 Brief for Defendant-Appellant, supra note 36, at 8 ("The closest governing
regulation, the Privacy Rule of . .. HIPAA, requires the removal of 18 specific
identifiers that relate to patient identity, including geographic subdivisions
smaller than a state, all elements of date (except year), biometric identifiers,
Social Security and medical record numbers."); 45 C.F.R. § 164.514(b)(2)
(2007).
89 According to the Electronic Privacy Information Center (EPIC), the
following states have legislation similar to the New Hampshire law pending (or
approved, but not yet effective): Arizona, the District of Columbia, Illinois,
Kansas, Maine, Maryland, Massachusetts, New York, North Carolina, Rhode
Island, Vermont, Washington, and West Virginia. See Electronic Privacy
Information Center, IMS Health v. Ayotte, http://epic.org/privacy/imshealth/
(last visited Apr. 2, 2009) (on file with the North Carolina Journal of Law &
Technology).
90 A federal judge in Vermont upheld a state law prohibiting the sale or use of
prescriber-identifiable data for the marketing of prescription drugs. IMS Health
Inc. v. Sorrell, 2008 U.S. Dist. LEXIS 47454 (D. Vt. Apr. 23, 2009).
91 Qualters, supra note 60.92 See American Medical Association (AMA), Physician Data Restriction
Program, http://www.ama-assn.org/ama/no-index/about-ama/12054.shtml (last
visited Apr. 2, 2009) (on file with the North Carolina Journal of Law &
Technology).
93 Id. Cf The Prescription Project, Prescription Data Mining Fact Sheet, 3,
Nov. 19, 2008, http://www.prescriptionproject.org/tools/solutions-factsheets/
files/0004.pdf ("Although the AMA initiated an option in 2006 to allow
physicians to 'opt out' of [granting access to their prescribing data], the process
is cumbersome and few physicians are aware of the option. Moreover, even
when a doctor 'opts out,' the AMA continues to sell that doctor's personally
identifiable prescribing information. Pharmaceutical companies may still use the
information to target their marketing efforts, as long as they pledge not to
provide that individual prescriber's data directly to salespeople. Furthermore,
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Furthermore, the pharmaceutical industry recently instituted some
restrictions on detailing: pharmaceutical companies must now
develop polices regarding the use of prescription data and
interactions with health care providers. 94 However, the industry
has not gone as far as to ban prescription data use.95
IV. FEDERAL PRESCRIPTION INFORMATION PRIVACY
REGULATION NEEDED
Similar to the federal statutes and regulations associated with
the finance industry-a traditional "paper" industry that has
somewhat successfully made the leap into the digital business
model-the health care industry could adopt federal laws to handle
its intricacies.96  Particularly, a need exists for a comprehensive,
national legal framework regarding the unauthorized commercial
use and disclosure of prescriber-identifiable prescription data. To
protect against threats to privacy, 97 a federal statute should apply to
entities that handle prescriber-identifiable data, regardless of their
primary business.98 Congress could utilize its Commerce Clause
the collection of prescribing data and identities through pharmacies is not
affected by the AMA policies.") (last visited Apr. 2, 2009) (on file with the
North Carolina Journal of Law & Technology).
94 The Pharmaceutical Research and Manufacturers of America (PhRMA),
PhRMA Code on Interactions with Healthcare Professionals, http://www.phrma.
org/code on interactions with healthcare-professionals/ (last visited Apr. 2,
2009) (on file with the North Carolina Journal of Law & Technology).
95 See id.
96 See, e.g., William A. Yasnoff, Electronic Records Are Key to Health-Care
Reform, BUSINESSWEEK.COM, Dec. 19, 2008, http://www.businessweek
.com/print/bwdaily/dnflash/content/dec2008/db20081218_385824.htm (The
electronic health record (EHR) is often analogized to a bank account.) (last
visited Apr. 2, 2009) (on file with the North Carolina Journal of Law &
Technology).
97 See, e.g., Solove, supra note 33. Cf Jennifer Peltz, Associated Press, Scalia
Speaks on Digital Privacy at NYC Conference, NEWSDAY.COM, Jan. 28, 2009,
http://www.newsday.com/news/local/wire/newyork/ny-bc-ny--justicescalia0128
jan28,0.4706132.story (U.S. Supreme Court Justice Antonin Scalia notes that
"Data such as drug prescriptions probably should be protected . . . suggesting
areas off-limits to data gatherers could simply be listed for legal purposes.").
98 As for potential First Amendment challenges, even if the court considers the
transfer or use of prescription data as commercial speech, a federal prescription
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power to regulate the use, transfer, license, and sale of prescription
data.99
Under the Commerce Clause,100 Congress has complete
plenary power when it comes to establishing rules for commercial
dealings that concern more than one state.101 Although Congress'
power to regulate interstate commerce is limited,102 the sale, use,
or transfer of prescriber-identifiable data for commercial purposes
is an activity that substantially affects interstate commerce.103
Congress' regulation of prescription data is important to protect the
data privacy of prescribers. Even if a state approves prescriber-
identifiable data use for commercial purposes, Congress could ban
its use as part of comprehensive regulation of pharmaceutical drug
selling.104 Additionally, in a landmark pharmaceutical product
liability case, os the Supreme Court recently held that the federal
drug-approval and warning-label standards106 do not preempt state
information law would likely be constitutional. See IMS Health, Inc. v. Ayotte,
550 F.3d 42, 52-53 (1st Cir. 2008), petition for cert. filed, 2009 WL 797587
(U.S. Mar. 27, 2009) (No. 08-1202) ("[S]peech-related regulations [exist] that
effectively lie beyond the reach of the First Amendment.") (emphasis added).
99 U.S. CONsT. art. I, § 8, cl. 3 ("Congress shall have [the] Power ... [t]o
regulate Commerce ... among the several States.").
100 Id.
101 See Gibbons v. Ogden, 22 U.S. 1 (1824).102 See United States v. Morrison, 529 U.S. 598 (2000); United States v.
Lopez, 514 U.S. 549 (1995) (Congress' power to regulate interstate commerce
includes power to regulate: channels of interstate commerce; instrumentalities of
interstate commerce; and activities that substantially affect interstate
commerce.).
103 See Gonzales v. Raich, 545 U.S. 1 (2005); Wickard v. Filburn, 317 U.S.
111 (1942).
104 See generally Gonzales, 545 U.S. 1.
10 Wyeth v. Levine, 129 S.Ct. 1187, 1190-92, 1204 (2009). A woman sued a
drug manufacturer after the incorrect administration of a drug caused her to
develop gangrene in her arm. The Court held that the Food and Drug
Administration's (FDA) approval of the pharmaceutical's label does not
preempt state law because of Congress's purpose. Id.
106 See Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. §355(a)-(d)
(2006). A drug manufacturer may not market a new drug prior to submitting a
new drug application to the FDA and receiving its approval. Id.
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laws.107 Relying on statutory interpretation, os the Court's decision
on whether federal laws that regulate certain products "preempt"
state tort law tilted toward consumer protection and away from
business interest.109
While prescription data is within Congress' power to regulate,
it may be difficult for Congress to pass a comprehensive law. Due
to the internal legislative process, it is often more difficult for
Congress to pass a comprehensive legislative scheme than a
piecemealed statute. Therefore, in the interim, Congress should
expand the scope of the HIPAA Privacy Rule to address the
disclosure and use of prescriber-identifiable prescription data.
Associated de-identification standards, similar to those protecting
PHI,110 should also be added to protect prescribers.
107 Wyeth, 129 S.Ct. at 1204 ("Wyeth has not persuaded us that failure to-warn
claims like Levine's obstruct the federal regulation of drug labeling. Congress
has repeatedly declined to pre-empt state law, and the FDA's recently adopted
position that state tort suits interfere with its statutory mandate is entitled to no
weight."); Ashby Jones, A Big Day for State Tort Laws: A Closer Look at Wyeth
v. Levine, WALL ST. J. L. BLOG, (Mar. 4, 2009), http://blogs.wsj.com/law/2009/
03/04/a-big-day-for-state-tort-law-a-closer-look-at-wyeth-v-levine/ (The Court
examined the specific statute and determined whether or not it could exist side-
by-side with state tort law.) (on file with the North Carolina Journal of Law &
Technology).
108 Wyeth, 129 S.Ct. at 1194-95 (citing Medtronic, Inc. v. Lohr, 518 U.S. 470,
485 (1996)) ("[I]n all preemption cases, and particularly in those in which
Congress has 'legislated . . . in a field which the States have traditionally
occupied,' . . . we 'start with the assumption that the historic police powers of
the States were not to be superseded by the Federal Act unless that was the clear
and manifest purpose of Congress."').
109 See Ashby Jones, A Big Day for State Tort Law: A Closer Look at Wyeth v.
Levine, WALL ST. J. L. BLOG, (Mar. 4, 2009), http://blogs.wsj.com/law/2009/03/
04/a-big-day-for-state-tort-law-a-closer-look-at-wyeth-v-levine/ ("The Court is
going to look at the statutory scheme, make a judgment on whether state action
is absolutely incompatible with federal law or not. If there's a tie, the Court, it
seems, is going to allow state lawsuits.") (last visited Mar. 10, 2009) (on file
with the North Carolina Journal of Law & Technology).
110 See HIPAA, supra note 13.
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V. CONCLUSION
The New Hampshire Prescription Information Law aims to
restrict disclosure and use of prescriber-identifiable data for
commercial marketing use. 11  The First Circuit's decision to
uphold the state law likely will encourage those states considering
similar legislation and create a trend toward increased regulation of
prescription data use.112 If states begin adopting these laws,
prescription data mining for commercial purposes would decrease,
mitigating threats to data privacy. However, with the court's
statutory interpretation in IMS Health and the current gap in
federal law, every jurisdiction in the United States would need the
same prescription information law for another state's law to
provide effective comity. Therefore, federal legislation should
help address the differences between varying state laws.
While the IMS Health decision supports the growing trend to
provide prescription information privacy, it seems to "pull the
wool over" the ever-increasing issue "of protecting personal
information at a time when technology can pull together previously
disparate pieces of an individual's history and target advertising by
logging a computer user's online travel." 13 Even with the New
Hampshire law, the privacy-threatening conduct that the legislature
intends to prohibit could still occur. Detailers are still able to use
prescribers' histories as targeted-marketing tools to promote the
sale of brand-name drugs, as long as detailers obtain prescription
data outside state borders.114 Meanwhile, well-meaning state law
may not be effective in protecting prescriber-identifiable
prescription data from unauthorized disclosure and use for
commercial purposes.115
See N.H. REV. STAT. ANN. § 318:47-f (2006).
112 See EPIC, supra note 89.
113 Peltz, supra note 97.
114 See IMS Health, Inc. v. Ayotte, 550 F.3d 42, 55-57 (lstCir. 2008), petition
for cert. filed, 2009 WL 797587 (U.S. Mar. 27, 2009) (No. 08-1202) (noting that
"pharmaceutical companies use detailing to promote the sale of brand-name
drugs, and those drugs cost significantly more than their generic counterparts.").
115 See, e.g., N.H. REv. STAT. ANN. § 318:47-f (2006).
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A national law emulating data protection standards is essential
for prescriber-identifiable data, especially as the U.S. health care
industry moves toward a Nationwide Health Information Network
(NHIN) and increasingly uses electronic health records (EHRs).1 16
Similarly, the U.S. Centers for Medicare and Medicaid Services
recently promulgated a new electronic prescribing incentive
program for physician payment. The program encourages
prescribers to trade-in their prescription pads for electronic
prescribing when ordering drugs for Medicare patients.118
Accordingly, in the future, more prescriber-identifiable data will
probably be electronically stored and transmitted. As the use of
health IT becomes more widespread and systems become
interconnected,1 19 data management will become increasingly
borderless and may exacerbate existing privacy concerns. In the
116 In an overall effort to establish a health information exchange, the U.S.
health care industry is developing a Nationwide Health Information Network to
make a variety of electronic records interoperable and accessible across the
country. See generally United States Department of Health and Human Services,
Nationwide Health Information Network, http://www.hhs.gov/healthit/
healthnetwork/background/ (last visited Apr. 2, 2009) (on file with the North
Carolina Journal of Law & Technology). Robert Pear, Privacy Issues
Complicates Push to Link Medical Data, N.Y. TIMES, Jan. 18, 2009, at A16,
available at http://www.nytimes.com/2009/01/18/us/politics/18health.html.
117 See Press Release, Centers for Medicare & Medicaid Services (CMS),
Final 2009 Physician Payment Rule Implements New Electronic Prescribing
Incentive Program, Oct. 30, 2008, http://www.cms.hhs.gov/apps/media/pre
ss/release.asp?Counter=3330 ("Approximately 980,000 physicians and non-
physicians practitioners (NPPs) bill Medicare under the [Medicare Physician
Fee Schedule] (MPFS) for the services they furnish to beneficiaries. Of these,
nearly 95 percent accept Medicare's fee schedule rate as payment in full for
their services."). See generally 73 Fed. Reg. 69847-69852, 2009 Physician Fee
Schedule (PFS) Rule (2008). The e-prescribing incentive program is authorized
under the Medicare Improvements for Patients and Providers Act of 2008
(MIPPA), § 132 P.L. 110-275 (2008).
118 See CMS, supra note 117 ("Physicians . . . [may] earn an incentive
par9ent of 2.0 percent of their total Medicare allowed charges.").
19 The President recently signed into law statutory provisions that promote
health information technology and nationalize adoption of electronic health
records. See American Recovery Reinvestment Act (ARRA), Health
Information Technology for Economic and Clinical Health Act (HITECH Act),
111 Pub. L. No. 5, § 13001, 123 Stat. 115 (2009).
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absence of federal regulation of the disclosure and use of
prescriber-identifiable prescription data, data mining and detailing
business practices will continue threatening prescriber data privacy
in order to enable business intelligence.
